Maxcyte (MXCT) Enterprise Value (2020 - 2026)

Maxcyte (MXCT) has 7 years of Enterprise Value data on file, last reported at -$106.9 million in Q1 2026.

• On a quarterly basis, Enterprise Value rose 22.72% year-over-year to -$106.9 million in Q1 2026; TTM through Mar 2026 was -$106.9 million, a 22.72% increase from a year earlier, with the FY2025 full-year figure at -$103.0 million, up 33.3% from the prior year.
• Enterprise Value for Q1 2026 stood at -$106.9 million, down from -$103.0 million in the prior quarter.
• Over the last five years, Enterprise Value for MXCT reached as high as -$103.0 million in Q4 2025 and fell as low as -$246.3 million in Q1 2022.
• Historically, Enterprise Value has averaged -$173.5 million across 5 years, with a median of -$157.5 million in 2024.
• Across the five-year window, Enterprise Value sank 228.22% in 2022 and jumped 33.3% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$227.3 million in 2022, then grew by 25.98% to -$168.3 million in 2023, then climbed by 8.2% to -$154.5 million in 2024, then soared by 33.3% to -$103.0 million in 2025, then declined by 3.7% to -$106.9 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$106.9 million in Q1 2026, -$103.0 million in Q4 2025, and -$105.7 million in Q3 2025.